<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04782375</url>
  </required_header>
  <id_info>
    <org_study_id>AMC 2021-0135</org_study_id>
    <nct_id>NCT04782375</nct_id>
  </id_info>
  <brief_title>Safely Discontinue Antiviral Treatment in Patients With Chronic Hepatitis B</brief_title>
  <acronym>ADAPT</acronym>
  <official_title>A Multicenter, Open-label, Randomized Controlled Trial to Safely Discontinue Antiviral Treatment in Patients With Chronic Hepatitis B (ADAPT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, Open-label, Randomized Controlled Trial Chronic hepatitis B male and female&#xD;
      adults on antiviral treatment for hepatitis B, without cirrhosis who are currently HBV DNA&#xD;
      (-) and HBeAg (-) To evaluate the safety and efficacy of stopping long-term antiviral therapy&#xD;
      in chronic hepatitis B patients without cirrhosis who are currently HBV DNA (-) and HBeAg (-)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial is a multicenter, open label, randomized controlled study to compare the&#xD;
      short-term clinical outcome between stopping and continuing antiviral treatment in chronic&#xD;
      hepatitis B patients without cirrhosis who are currently HBV DNA (-) and HBeAg (-)&#xD;
      Approximately 280 subjects meeting eligibility criteria will be enrolled and randomized (1:1)&#xD;
      to Treatment Arm (A) or Treatment Arm (B), as below;&#xD;
&#xD;
        -  Treatment Arm A: 140 subjects, discontinue antiviral treatment (stop group)&#xD;
&#xD;
        -  Treatment Arm B: 140 subjects, continue antiviral treatment (continue group) This study&#xD;
           was designed to randomly assign treatment groups to subjects in order to prevent biases&#xD;
           that may be intervened, and to increase comparability between the groups. Since&#xD;
           post-treatment HBsAg titer could affect the clinical outcome in the eligible subjects,&#xD;
           randomization will be stratified by post-treatment HBsAg titer (≥100 IU/mL or &lt;100&#xD;
           IU/mL) at screening at a 1:1 ratio by using centralized stratified block randomization.&#xD;
&#xD;
      Both groups (i.e. Treatment Arm A and B) are scheduled to be followed up to 2 years. Patients&#xD;
      in the Treatment Arm A (stop group) were retreated with nucleos(t)ide analogues that had been&#xD;
      prescribed previously if they fulfill one of the following criteria: 1) HBV DNA &gt;2,000 IU/mL,&#xD;
      2) progression to liver cirrhosis, or 3) development of hepatocellular carcinoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>virological relapse</measure>
    <time_frame>Change from baseline in HBV DNA result at 2year</time_frame>
    <description>Proportion of virological relapse defined as HBV DNA ≥2,000 IU/mL</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Treatment Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>discontinue antiviral treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>continue antiviral treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stop group</intervention_name>
    <description>discontinue antiviral treatment</description>
    <arm_group_label>Treatment Arm A</arm_group_label>
    <other_name>discontinue antiviral treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Continue group</intervention_name>
    <description>continue antiviral treatment</description>
    <arm_group_label>Treatment Arm B</arm_group_label>
    <other_name>continue antiviral treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing and able to provide written informed consent prior to study entry&#xD;
&#xD;
          2. Age ≥19 years and ≤55 years at the time of screening&#xD;
&#xD;
          3. At least once, confirmation HBeAg(+) prior study enrollment&#xD;
&#xD;
          4. HBsAg titer &lt;1,000 IU/mL at the time of screening&#xD;
&#xD;
          5. Antiviral treatment continued at least 2 years after HBeAg seroclearance (HBeAg (-) at&#xD;
             the time of screening)&#xD;
&#xD;
          6. Undetectable HBV DNA level at the time of screening&#xD;
&#xD;
          7. Serum ALT level &lt;40 IU/mL at the time of screening&#xD;
&#xD;
          8. Estimated creatinine clearance ≥30 ml/min (by calculation of creatinine clearance or&#xD;
             using the CKD-EPI equation)&#xD;
&#xD;
          9. Ability to comply with all study requirements including 2-month visit interval&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Confirmed known co-infection with HCV, HIV, or HDV&#xD;
&#xD;
          2. Evidence of liver cirrhosis defined as meeting any of the following criteria:&#xD;
&#xD;
          3. Current alcohol (60g/day) or substance abuse judged by the investigator that will&#xD;
             potentially interfere with subject compliance (1) Splenomegaly (&gt;12 cm) assessed by&#xD;
             ultrasound, CT, or MRI (2) Fibroscan ≥9.0 kPa (3) Platelet count &lt;150,000/mm3 However,&#xD;
             if the above criteria were satisfied at the time of antiviral treatment initiation,&#xD;
             subjects may be eligible if they have low possibility of having liver cirrhosis with&#xD;
             improvement in liver function by long-term antiviral treatment, following the opinion&#xD;
             of the investigator.&#xD;
&#xD;
          4. Any history of, or current evidence of, clinical hepatic decompensation (e.g.,&#xD;
             ascites, encephalopathy, variceal hemorrhage, or Child-Pugh score of ≥7) at the time&#xD;
             of screening&#xD;
&#xD;
          5. Currently on or have received therapy with Interferon or immunosuppressant (including&#xD;
             systemic chemotherapy) within 12 months prior to the screening&#xD;
&#xD;
          6. Requirement for chronic use of systemic immunosuppressant including, but not limited&#xD;
             to, corticosteroid (prednisone equivalent of &gt;40 mg/day for &gt;2 weeks), azathioprine,&#xD;
             or monoclonal antibodies&#xD;
&#xD;
          7. Received solid organ or bone marrow transplant&#xD;
&#xD;
          8. Any other clinical conditions (cardiovascular, respiratory, neurologic, or renal&#xD;
             conditions) or prior therapy that, in the opinion of the investigator, would make the&#xD;
             subject unsuitable for the study or unable to comply with dosing requirements.&#xD;
&#xD;
          9. History or current evidence of hepatocellular carcinoma (HCC), or high α-fetoprotein&#xD;
             (AFP) &gt; 20 ng/mL. But, the patients with AFP &gt; 20 ng/mL can be enrolled if AFP shows&#xD;
             decreasing trend and there is no evidence of HCC by dynamic CT or MRI)&#xD;
&#xD;
         10. Malignancy other than hepatocellular carcinoma within the 5 years prior to screening,&#xD;
             with the exception of specific cancers that are cured by surgical resection (within 2&#xD;
             years prior to screening with confirmation of no evidence of disease). Subjects under&#xD;
             evaluation for possible malignancy are not eligible.&#xD;
&#xD;
         11. Concurrent enrollment in another clinical study for other type of antiviral treatment&#xD;
             for CHB or immune modulatory drug within 3 months prior to randomization,&#xD;
             participation to an observational (non-interventional) clinical studies or&#xD;
             interventional studies not using anti-HBV or immune modulatory drugs, or during the&#xD;
             follow-up period of an interventional study are not exclusion criteria.&#xD;
&#xD;
         12. Pregnant women, women who are breastfeeding or who believe they may wish to become&#xD;
             pregnant during the course of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young-Suk Lim, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Young-Suk Lim, PhD</last_name>
    <phone>82-2-3010-3190</phone>
    <email>limys@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Soo Young Park</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Young-Suk Lim, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hyung Joon Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Konkuk University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>So Young Kwon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji Hoon Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyung-Hee University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gi-Ae Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wonseok Kang, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeong Hoon Lee</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeong Won Jang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Neung-Hwa Park</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Young-Suk Lim</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

